Skip to main
NRIX

NRIX Stock Forecast & Price Target

NRIX Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nurix Therapeutics is a promising biopharmaceutical company with a strong integrated discovery platform that has the potential to bring targeted protein degradation therapies for cancer and inflammatory diseases to market. Their pipeline includes multiple drug candidates that have shown promising preclinical and clinical results, and their unique approach to targeting specific proteins sets them apart from competitors in the industry. Despite the company's current net loss and need for additional funding, their collaborations and milestone payments provide potential for future financial growth. Based on their innovative platform and promising pipeline, Nurix Therapeutics has a positive outlook for investors.

Bears say

Nurix Therapeutics is a biopharmaceutical company with potential in CNS-involved tumors due to positive preclinical data on its drug candidates. However, the company is still in the early stages of clinical development, and its financials only reflect collaboration revenues and cash on hand. The recent interest from major pharma companies in novel degrader-antibody conjugates, like those being developed by Nurix, may be a positive sign but it is still too early to accurately predict the success of these programs.

NRIX has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nurix Therapeutics, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nurix Therapeutics, Inc (NRIX) Forecast

Analysts have given NRIX a Buy based on their latest research and market trends.

According to 13 analysts, NRIX has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nurix Therapeutics, Inc (NRIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.